[go: up one dir, main page]

AR001779A1 - Preparación terapéutica su uso dispositivo de inhalación de polvo seco y procedimientos de manufactura de dicha preparación - Google Patents

Preparación terapéutica su uso dispositivo de inhalación de polvo seco y procedimientos de manufactura de dicha preparación

Info

Publication number
AR001779A1
AR001779A1 AR33475995A AR33475995A AR001779A1 AR 001779 A1 AR001779 A1 AR 001779A1 AR 33475995 A AR33475995 A AR 33475995A AR 33475995 A AR33475995 A AR 33475995A AR 001779 A1 AR001779 A1 AR 001779A1
Authority
AR
Argentina
Prior art keywords
preparation
dry powder
inhalation device
manufacturing procedures
powder inhalation
Prior art date
Application number
AR33475995A
Other languages
English (en)
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9404449A external-priority patent/SE9404449D0/xx
Priority claimed from SE9502576A external-priority patent/SE9502576D0/xx
Application filed by Astra Ab filed Critical Astra Ab
Publication of AR001779A1 publication Critical patent/AR001779A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una preparación terapéutica que contiene la hormona paratiroide útil para el tratamiento de la osteoporosis en mamíferos. Más particularmente, dichapreparación comprende una hormona paratiroide humana de longitud total u homólogos de lamism a en forma de un polvo seco que es apropiado parainhalación en el cual por lo menos el 50% de dicho polvo seco consiste en (a) partículas que tienen un diámetro de hasta 10 micrones; o b) aglomerados dedichas partículas. Además se dan aconocer pro cedimientos para la manufactura de dicha preparación, un dispositivo de inhalación y los usos de dichapreparación en dicho dispositivo.
AR33475995A 1994-12-22 1995-12-21 Preparación terapéutica su uso dispositivo de inhalación de polvo seco y procedimientos de manufactura de dicha preparación AR001779A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9404449A SE9404449D0 (sv) 1994-12-22 1994-12-22 Therapeutic preparations for inhalation
SE9502576A SE9502576D0 (sv) 1995-07-12 1995-07-12 Therapeutic preparations for inhalation II

Publications (1)

Publication Number Publication Date
AR001779A1 true AR001779A1 (es) 1997-12-10

Family

ID=26662192

Family Applications (1)

Application Number Title Priority Date Filing Date
AR33475995A AR001779A1 (es) 1994-12-22 1995-12-21 Preparación terapéutica su uso dispositivo de inhalación de polvo seco y procedimientos de manufactura de dicha preparación

Country Status (27)

Country Link
US (2) US6436902B1 (es)
EP (2) EP1283035A3 (es)
JP (1) JPH10511090A (es)
KR (1) KR100389080B1 (es)
CN (1) CN1170527C (es)
AR (1) AR001779A1 (es)
AT (1) ATE238043T1 (es)
AU (1) AU703532B2 (es)
BR (1) BR9510516A (es)
CA (1) CA2206657C (es)
CZ (1) CZ182297A3 (es)
DE (1) DE69530519T2 (es)
DK (1) DK0806945T3 (es)
EE (1) EE9700136A (es)
ES (1) ES2197212T3 (es)
FI (1) FI972652A7 (es)
HU (1) HU218940B (es)
IL (1) IL116492A (es)
IS (1) IS4502A (es)
MX (1) MX9704544A (es)
NO (1) NO320432B1 (es)
NZ (1) NZ297921A (es)
PL (1) PL321094A1 (es)
PT (1) PT806945E (es)
SK (1) SK76797A3 (es)
TR (1) TR199501635A1 (es)
WO (1) WO1996019206A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6794357B1 (en) 1993-06-24 2004-09-21 Astrazeneca Ab Compositions for inhalation
US6632456B1 (en) * 1993-06-24 2003-10-14 Astrazeneca Ab Compositions for inhalation
US5830853A (en) 1994-06-23 1998-11-03 Astra Aktiebolag Systemic administration of a therapeutic preparation
JP4155594B2 (ja) 1994-12-22 2008-09-24 アストラゼネカ・アクチエボラーグ エアゾール製剤
EP0969816B1 (en) * 1997-03-20 2004-12-15 Schering Corporation Preparation of powder agglomerates
US6495167B2 (en) 1997-03-20 2002-12-17 Schering Corporation Preparation of powder agglomerates
US6503537B2 (en) 1997-03-20 2003-01-07 Schering Corporation Preparation of powder agglomerates
DZ2873A1 (fr) * 1998-08-19 2003-12-15 Lilly Co Eli Procédé pour augmenter la dureté et la rigidité osseuse.
AU1447600A (en) 1998-10-22 2000-05-08 Thomas J. Gardella Bioactive peptides and peptide derivatives of parathyroid hormone (pth) and parathyroid hormone-related peptide (pthrp)
EP1604024A4 (en) * 2000-04-06 2008-04-23 Wayne P Franco METHODS OF USING GROWTH FACTORS FOR TREATING CARDIOPATHY
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
AU2004292954A1 (en) * 2003-11-13 2005-06-09 Alza Corporation Composition and apparatus for transdermal delivery
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US20070020298A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid
KR20070007075A (ko) 2003-12-31 2007-01-12 사이덱스 인크 술포알킬 에테르 시클로덱스트린 및 코르티코스테로이드를함유한 흡입용 제형
US20050191360A1 (en) * 2004-02-10 2005-09-01 Advanced Inhalation Research, Inc. Particles for inhalation having rapid release properties
DE602004023765D1 (de) * 2004-03-12 2009-12-03 Trinity College Dublin Magnetoresistives medium
CN101098678A (zh) 2004-04-23 2008-01-02 锡德克斯公司 含有磺基烷基醚环糊精的dpi制剂
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
CN101355959B (zh) * 2005-11-10 2013-02-27 密歇根理工大学管理委员会 黑熊甲状旁腺素和使用黑熊甲状旁腺素的方法
US20070197486A1 (en) * 2005-12-20 2007-08-23 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids
US20070249572A1 (en) * 2005-12-20 2007-10-25 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
US20070185066A1 (en) * 2005-12-20 2007-08-09 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
US20070160542A1 (en) * 2005-12-20 2007-07-12 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile
US20070178049A1 (en) * 2005-12-20 2007-08-02 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids having an enhanced pharmacokinetic profile
US20070191327A1 (en) * 2006-02-15 2007-08-16 Verus Pharmaceuticals, Inc. Sterilization of corticosteroids with reduced mass loss
US12370352B2 (en) 2007-06-28 2025-07-29 Cydex Pharmaceuticals, Inc. Nasal and ophthalmic delivery of aqueous corticosteroid solutions
BRPI0814962B8 (pt) 2007-08-01 2021-05-25 Chugai Pharmaceutical Co Ltd métodos in vitro para determinar se um composto candidato é um agonista de longa duração ou de curta duração de um receptor acoplado à proteína g, polipeptídeo, seu uso e composição farmacêutica
EP2509996A1 (en) 2009-12-07 2012-10-17 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
US9492508B2 (en) 2010-05-13 2016-11-15 The General Hospital Corporation Parathyroid hormone analogs and uses thereof
WO2012130193A1 (en) 2011-03-31 2012-10-04 Zentiva, K.S. Non-covalent soluble complexes of teriparatide with polysaccharides and a dosage form of teriparatide for oral administration
US10266228B2 (en) 2016-06-24 2019-04-23 Easy2.Company B.V. Drive train for a treadle scooter
US20230190880A1 (en) * 2020-03-30 2023-06-22 Sichuan Luzhou Buchang Bio-Pharmaceutical Co., Ltd. Formulations of Human Parathyroid Hormone (PTH) and Methods for Producing Same

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE261096C (es)
BE556587A (es) 1957-01-31 1957-04-11
US2992645A (en) 1958-05-06 1961-07-18 Benger Lab Ltd Disperser for powders
GB1144905A (en) * 1965-03-25 1969-03-12 Fisons Pharmaceuticals Ltd Substituted bis-(2-carboxy-chromonyl-oxy) derivatives and preparation and pharmaceutical compositions thereof
GB1242211A (en) 1967-08-08 1971-08-11 Fisons Pharmaceuticals Ltd Pharmaceutical composition
GB1569611A (en) 1976-01-23 1980-06-18 Fisons Ltd Pelletised or granular medicament formulation
GB1520247A (en) 1974-08-10 1978-08-02 Fisons Ltd Pelletised medicament formulations
DE2750090A1 (de) * 1976-11-19 1978-06-01 Sandoz Ag Neue verabreichungsformen fuer organische verbindungen
SE7812207L (sv) * 1977-12-01 1979-06-02 Welsh Nat School Med Apparat, forfarande och framstellda produkter for anvendning vid administration av antihistaminer
JPS6034925B2 (ja) 1979-07-31 1985-08-12 帝人株式会社 持続性鼻腔用製剤およびその製造法
US4900730A (en) 1981-01-14 1990-02-13 Toyo Jozo Co., Ltd. Preparation which promotes the absorption of peptides
DE3274065D1 (de) * 1981-07-08 1986-12-11 Draco Ab Powder inhalator
SE438261B (sv) * 1981-07-08 1985-04-15 Draco Ab Anvendning i dosinhalator av ett perforerat membran
US5260306A (en) * 1981-07-24 1993-11-09 Fisons Plc Inhalation pharmaceuticals
JPS59163313A (ja) 1983-03-09 1984-09-14 Teijin Ltd 経鼻投与用ペプチドホルモン類組成物
US4548922A (en) * 1983-06-06 1985-10-22 Beth Israel Hospital Drug administration
US4746508A (en) * 1983-06-06 1988-05-24 Beth Israel Hospital Assn. Drug administration
US4959358A (en) * 1983-06-06 1990-09-25 Beth Israel Hospital Assn. Drug administration
US4963367A (en) 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
US5288498A (en) * 1985-05-01 1994-02-22 University Of Utah Research Foundation Compositions of oral nondissolvable matrixes for transmucosal administration of medicaments
US4537772A (en) * 1984-05-02 1985-08-27 Merck & Co., Inc. Enhancing absorption of drugs from gastrointestinal tract using acylcarnitines
JPS61267528A (ja) 1984-11-26 1986-11-27 Yamanouchi Pharmaceut Co Ltd 吸収促進剤を含有するカルシトニン経鼻剤
SE448277B (sv) * 1985-04-12 1987-02-09 Draco Ab Indikeringsanordning vid en doseringsanordning for lekemedel
US5122127A (en) 1985-05-01 1992-06-16 University Of Utah Apparatus and methods for use in administering medicaments by direct medicament contact to mucosal tissues
AU587472B2 (en) 1985-05-22 1989-08-17 Liposome Technology, Inc. Liposome inhalation method and system
US4847298A (en) 1985-08-16 1989-07-11 Merck & Co., Inc. Acylcarnitines as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal compartments
US4731360A (en) * 1985-08-16 1988-03-15 Merck & Co., Inc. Acylcarnitines as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal compartments
SE453566B (sv) 1986-03-07 1988-02-15 Draco Ab Anordning vid pulverinhalatorer
JPS632932A (ja) 1986-06-23 1988-01-07 Teijin Ltd 経鼻投与用粉末状組成物
DE3784594T2 (de) 1986-08-11 1994-01-05 Innovata Biomed Ltd Mikrokapseln enthaltende pharmazeutische Zusammensetzungen.
US5179079A (en) 1986-12-16 1993-01-12 Novo Nordisk A/S Nasal formulation and intranasal administration therewith
GB8712176D0 (en) 1987-05-22 1987-06-24 Cosmas Damian Ltd Drug delivery system
US5059587A (en) * 1987-08-03 1991-10-22 Toyo Jozo Company, Ltd. Physiologically active peptide composition for nasal administration
JP2851627B2 (ja) 1987-10-15 1999-01-27 シンテックス（ユー・エス・エイ）インコーポレイテッド 粉末形態ポリプペチド類の経鼻投与
JPH01117825A (ja) 1987-10-28 1989-05-10 Sanwa Kagaku Kenkyusho Co Ltd 鼻くう、副鼻くう投与用製剤及びその使用方法並びにその形状及び使用器具
EP0360340A1 (en) 1988-09-19 1990-03-28 Akzo N.V. Composition for nasal administration containing a peptide
US5997856A (en) 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
JPH02104531A (ja) 1988-10-14 1990-04-17 Toyo Jozo Co Ltd 経鼻投与用生理活性ペプチド組成物
US5006343A (en) 1988-12-29 1991-04-09 Benson Bradley J Pulmonary administration of pharmaceutically active substances
US4994439A (en) 1989-01-19 1991-02-19 California Biotechnology Inc. Transmembrane formulations for drug administration
US5011678A (en) * 1989-02-01 1991-04-30 California Biotechnology Inc. Composition and method for administration of pharmaceutically active substances
DE69027022T2 (de) 1989-02-17 1996-11-28 Liposome Co Inc Lipidhilfstoffe für verabreichung durch die nase und örtliche anwendung
IT8920486A0 (it) 1989-05-12 1989-05-12 Isf Spa Composizioni farmaceutiche.
US5176132A (en) 1989-05-31 1993-01-05 Fisons Plc Medicament inhalation device and formulation
JP2642486B2 (ja) 1989-08-04 1997-08-20 田辺製薬株式会社 難溶性薬物の超微粒子化法
GB8921222D0 (en) 1989-09-20 1989-11-08 Riker Laboratories Inc Medicinal aerosol formulations
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
US5376386A (en) * 1990-01-24 1994-12-27 British Technology Group Limited Aerosol carriers
GB9001635D0 (en) * 1990-01-24 1990-03-21 Ganderton David Aerosol carriers
US5118494A (en) 1990-03-23 1992-06-02 Minnesota Mining And Manufacturing Company Use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations
JPH05963A (ja) 1990-04-13 1993-01-08 Toray Ind Inc ポリペプチド類組成物
US5192548A (en) * 1990-04-30 1993-03-09 Riker Laboratoires, Inc. Device
CA2081474A1 (en) 1990-05-08 1991-11-09 Manzer Durrani Direct spray-dried drug/lipid powder composition
JPH0441421A (ja) 1990-06-07 1992-02-12 Taisho Pharmaceut Co Ltd 肺吸収組成物
SE9002895D0 (sv) 1990-09-12 1990-09-12 Astra Ab Inhalation devices for dispensing powders i
GB9020544D0 (en) * 1990-09-20 1990-10-31 Sandoz Ltd Improvements in or relating to organic compounds
JPH04149126A (ja) 1990-10-09 1992-05-22 Mitsubishi Kasei Corp 経粘膜投与用医薬組成物
IL99699A (en) * 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
DE4039656A1 (de) * 1990-12-12 1992-06-17 Bissendorf Peptide Gmbh Arzneimittel, enthaltend das humane parathormon-fragment (1-37) in der form des amids oder ethylamids als aktiven wirkstoff
NZ241954A (en) 1991-03-15 1994-01-26 Amgen Inc Compositions of g-csf for pulmonary administration.
US5320094A (en) 1992-01-10 1994-06-14 The Johns Hopkins University Method of administering insulin
CA2127877A1 (en) 1992-01-21 1993-07-22 Robert M. Platz Improved process for preparing micronized polypeptide drugs
EP0566135A1 (en) 1992-04-17 1993-10-20 Takeda Chemical Industries, Ltd. Transmucosal composition comprising a peptide and a cytidine derivative
US5376359A (en) * 1992-07-07 1994-12-27 Glaxo, Inc. Method of stabilizing aerosol formulations
NZ257212A (en) * 1992-09-29 1996-11-26 Inhale Therapeutic Syst Parathyroid hormone formulations comprising a biologically active n-terminal fragment of the hormone
JPH08509465A (ja) 1993-01-29 1996-10-08 マイリス メディカル コーポレーション ホルモンの肺内送達
US5364838A (en) 1993-01-29 1994-11-15 Miris Medical Corporation Method of administration of insulin
DE69413528T2 (de) 1993-04-06 1999-05-06 Minnesota Mining And Mfg. Co., Saint Paul, Minn. Vorrichtung zum deagglomerieren für trockenpulverinhalatoren
US5506203C1 (en) 1993-06-24 2001-02-06 Astra Ab Systemic administration of a therapeutic preparation
IS1796B (is) * 1993-06-24 2001-12-31 Ab Astra Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
US5747445A (en) 1993-06-24 1998-05-05 Astra Aktiebolag Therapeutic preparation for inhalation
TW402506B (en) 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
US5661130A (en) 1993-06-24 1997-08-26 The Uab Research Foundation Absorption enhancers for drug administration
US5349947A (en) 1993-07-15 1994-09-27 Newhouse Michael T Dry powder inhaler and process that explosively discharges a dose of powder and gas from a soft plastic pillow
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
KR100419037B1 (ko) 1994-03-07 2004-06-12 넥타르 테라퓨틱스 폐를통한인슐린의전달방법및그조성물
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
US5451569A (en) 1994-04-19 1995-09-19 Hong Kong University Of Science And Technology R & D Corporation Limited Pulmonary drug delivery system
BR9610492A (pt) 1995-09-21 1999-03-30 Andaris Ltd Veículos e intensificadores de transcitose para liberação de droga

Also Published As

Publication number Publication date
US20020115588A1 (en) 2002-08-22
MX9704544A (es) 1997-10-31
EP0806945A1 (en) 1997-11-19
KR100389080B1 (ko) 2003-10-17
US20030064928A1 (en) 2003-04-03
NO320432B1 (no) 2005-12-05
NO972715L (no) 1997-06-12
HUT77738A (hu) 1998-07-28
TR199501635A1 (tr) 1996-10-21
PT806945E (pt) 2003-09-30
JPH10511090A (ja) 1998-10-27
EP0806945B1 (en) 2003-04-23
CZ182297A3 (cs) 1998-01-14
CN1170361A (zh) 1998-01-14
SK76797A3 (en) 1998-02-04
DK0806945T3 (da) 2003-08-04
ES2197212T3 (es) 2004-01-01
PL321094A1 (en) 1997-11-24
IL116492A0 (en) 1996-03-31
AU703532B2 (en) 1999-03-25
EE9700136A (et) 1997-12-15
NO972715D0 (no) 1997-06-12
EP1283035A2 (en) 2003-02-12
EP1283035A3 (en) 2003-03-19
IL116492A (en) 2000-08-13
IS4502A (is) 1997-06-09
BR9510516A (pt) 1998-07-07
DE69530519D1 (de) 2003-05-28
DE69530519T2 (de) 2004-03-04
CN1170527C (zh) 2004-10-13
NZ297921A (en) 2001-05-25
FI972652L (fi) 1997-08-18
US6436902B1 (en) 2002-08-20
FI972652A0 (fi) 1997-06-19
ATE238043T1 (de) 2003-05-15
CA2206657A1 (en) 1996-06-27
AU4319996A (en) 1996-07-10
WO1996019206A1 (en) 1996-06-27
CA2206657C (en) 2009-05-19
HU218940B (hu) 2001-01-29
FI972652A7 (fi) 1997-08-18

Similar Documents

Publication Publication Date Title
AR001779A1 (es) Preparación terapéutica su uso dispositivo de inhalación de polvo seco y procedimientos de manufactura de dicha preparación
CL2004001191A1 (es) Compuestos derivados de esteroides 17 alpha-fluoroalquilados, con actividad antigestagena; composicion farmaceutica; combinacion farmaceutica; y uso del compuesto en la preparacion de un medicamento antiestrogenico, para el tratamiento de dismenorrea
ES2130217T3 (es) Uso de tiloxapol como dispersante y estabilizante de nanoparticulas.
MX9702357A (es) Microparticulas secadas por aspersion como vehiculos terapeuticos.
DK0517797T3 (da) Anvendelse af D-vitaminanaloger i behandlingen af akne
PE19496A1 (es) Formulacion de analogo de insulina humana
ES2015044B3 (es) Proceso para la preparacion de aglomerados que contienen acido diperoxido-decanodioico y su uso en composiciones de blanqueo.
ES2010648T3 (es) Formulaciones farmaceuticas de sustancias labiles frente a los acidos para uso oral.
AR018109A1 (es) FORMULACIoN GALÉNICA ADMINISTRABLE POR VíA ORAL QUE PERMITE UNA ABSORCIoN MEJORADA DE PRINCIPIOS ACTIVOS, USO DE UN AGENTE MAJORADOR DE ABSORCIoN PARA PREPARAR UNA FORMA DE DOSIFICACIoN ADMINISTRABLE POR VíA ORAL Y PROCEDIMIENTO PARA PREPARAR DICHA FORMULACIoN GALÉNICA
DE60033445D1 (de) Handschuh mit aloe vera und sein herstellungsverfahren
FI950169L (fi) PTH:n ja PTHRP:n analogit, niiden synteesi ja käyttö osteoporoosin hoitoon
BR9813677A (pt) Composição para cuidado oral, e, uso de um ácido poliacrìlico totalmente neutralizado
IT1283102B1 (it) Composizione terapeutica per la somministrazione transdermica di un principio attivo estrogeno o progestinico o di loro miscele
ES2121616T3 (es) Composicion cosmetica para el maquillaje en forma de una mascarilla que contiene por lo menos una cera y un pseudolatex de derivados de la celulosa.
BR8502395A (pt) Processo para a preparacao de 1-heteroaril-4-aril-pirazolin-5-onas,composicoes microbicidas,processos para o combate de microbios e para a preparacao de composicoes e utilizacao
PA8562101A1 (es) Metodos para granulacion humeda de azitromicina
IT1141482B (it) Sali misti di amminoacidi essenziali o semi-essenziali e loro analoghi non azotati,nonche' loro impiego nella terapia di disfunzioni renali ed epatiche
BR9711311A (pt) Composto composi-Æo farmac-utica uso de um composto e processos para a prepara-Æo de compostos e para tratamento de um mamifero incluindo o homem
ES2149082B1 (es) Nueva formulacion para inhalacion.
SE8803935D0 (sv) Laekemedelskomposition
NO169324C (no) Fremgangsmaate til fremstilling av toerrstoffer oppnaadd vedlyofilisering og egnet til fremstilling av stabile suspensjoner
FI900315A0 (fi) Saett att framstaella ett ytligt terapeutiskt system vilket innehaoller tillvaext av elakartade celler och tillvaextfoerhindrande aktivaemne, speciellt 5-fluoruracil.
ES2087279T3 (es) El uso de giberelinas para el tratamiento de la prostatitis y la psoriasis.
IT1241396B (it) Composizioni tensioattive, loro preparazione e loro impiego come agenti antischiuma. (caso 150-5294)
JPS6440421A (en) Medical sheetlike tacky agent

Legal Events

Date Code Title Description
FB Suspension of granting procedure